Very good vision although a little bit late. The current FDA approval process just drive bio and pharma companies to shift their capital away from the US which is badly in need of accelerated development of its bio and pharma manufacturing to overcome the current economic downturn. The chance of the USA missing the bio-tech and pharma-tech boats is looming larger and larger as I can see given the slow speed of FDA process coupled with budget cutback.IMHO.
HTX Price at posting:
1.6¢ Sentiment: None Disclosure: Held
